PROTECTOR is a multicentre, national prospective cohort surgical study for premenopausal women who are at increased risk of developing ovarian cancer either because of a genetic mutation (BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2) or a strong family history of ovarian and breast cancer or ovarian cancer alone.

The study is being coordinated from Barts Cancer Institute, Queen Mary University of London, and is funded by Barts and The London Charity and Rosetrees Trust.

Aims and Objectives
The primary objective is to evaluate the impact on sexual function with RRESDO as a two-step ovarian cancer prevention strategy in premenopausal women at increased risk of ovarian cancer.

Study Arms
Participants will be able to self-select which arm of the study they wish to take part in:

We currently have 42 hospitals across England, Wales, Scotland and Northern Ireland which are recruiting participants to PROTECTOR. Our recruitment target is 1250 participants. If you would like to become a recruiting centre please contact our team. To enrol a patient into the PROTECTOR study, please refer to your nearest recruitment centre which can be found using our interactive map.